Luciole Medical is a Zurich, Switzerland–based developer of a platform of next-generation brain monitoring devices. Its minimally-invasive probe measures oxygenated and de-oxygenated hemoglobin content and cerebral blood flow to provide information on tissue metabolism and brain function. The company received CE mark in 2016 for the minimally invasive probe for use in comatose patients following stroke or traumatic brain injury. A non-invasive patch that measures oxygen saturation and blood flow of brain tissue is under development for use in anesthesia and other conditions at risk of desaturation. Luciole Medical closed a CHF 5.3m Series A to initiate commercialization of the minimally-invasive probe for intensive care patients and to further develop the non-invasive patch for surgical/anesthesia applications. The company is a spin-out from the Swiss Polytechnic Institute and the University of Zürich and is led by CEO Dr. Philippe Dro.

Total raised

$6M

Funding rounds

1

Latest round

Series A

Latest activity

Sep 2018